Mergers & Acquisitions ·
On September 1, 2026, Crinetics Pharmaceuticals completed its merger with Vertex Pharmaceuticals, becoming a wholly…
CRNXCrinetics Pharmaceuticals, Inc.
On September 1, 2026, Crinetics Pharmaceuticals completed its merger with Vertex Pharmaceuticals, becoming a wholly owned subsidiary. Each outstanding share of Crinetics common stock was canceled and converted into the right to receive $85.00 per share in cash. The aggregate consideration paid by Vertex was approximately $10.0 billion, funded through cash on hand and borrowings under Vertex’s term loan credit agreement. Upon closing, all incumbent directors resigned, and Vertex appointed Charles Wagner as President, Prasanna Thombre as Treasurer, and Omar White as Secretary of the surviving corporation. Crinetics' common stock was delisted from Nasdaq, and its registration under Section 12(b) of the Exchange Act was terminated. Crinetics Pharmaceuticals operates in the biotechnology industry, focusing on the development of targeted therapies for inflammatory and immune-mediated diseases.